A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Short Course Daratumumab in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE2
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2